PHRI research on diabetes is well represented at the 55th annual meeting of the European Association for the Study of Diabetes (EASD 2019) in Barcelona, Spain Sept. 16 – 20, 2019.
- Unique features and findings of the long-term REWINDÂ (researching cardiovascular events with a weekly incretin in diabetes) trial, presented by PHRI Senior Scientist Hertzel Gerstein. Sept. 19, 12:00 Barcelona time, Vilanova Hall.
- REMIT-DAPA trial (diabetes regression and remission following a short-term intensive metabolic intervention with insulin glargine, metformin and dapagliflozin) poster presentation by PHRI Investigator Natalia McInnes. Sept. 19, 13:15.
- Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomization study: oral presentation by PHRI Investigator Marie Pigeyre, Sept. 19, 15:00, Serrano-Rios Hall.
Marie Pigeyre
- Novel biomarkers predicting renal decline in people with dysglycemia in the ORIGIN trial: oral presentation by Hertzel Gerstein, Sept. 19, 15:30, Vilanova Hall.
Next month, PHRI will share research at the 2019 Diabetes Canada/Canadian Society of Endocrinology and Metabolism professional conference, in Winnipeg, Canada.
